Dirk Schadendorf
German Cancer Research Center · 2,453 works · 223,851 citations · h-index 183
Top works
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- A Landscape of Driver Mutations in Melanoma
- Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- The Immune Landscape of Cancer
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- Genomic Classification of Cutaneous Melanoma